Matinas Biopharma Holdings Inc (MTNB)

[The Lawman]

Many catalysts are on the horizon in the coming weeks and months. Topline Phase I results to be announced in 1Q 2017 for amikacin, Topline Phase II results to be announced in 1H 2017 for amphotericin b, and uplisting to NYSE Market is imminent.

Matinas' is also planning to do a clinical trial for the prophylactic use of amphotercin b.

Along the way, I would expect licensing deals whereby pharmaceutical companies pay to use Matinas' patented cochletate technology for effective but toxic drugs that can be safely and effectively administered through use of this platform. This would allow Matinas to grow, and increase value, while getting the money needed for Phase III trials.

Value-wise compare Matinas to Insmed (INSM), which has a $950M market cap while having only one product: a nebulized form of amaikacin that may possibly have significant side effects.

In contrast, Matinas has an oral encochleated form of amikacin that appears to have few, if any, side effects, and is a platform for the safe and effective use of dozens of other drugs (such as but by no means limited to amphotericin b) that are effective but too toxic to be used except as a last resort for very short periods of time.

Matinas is like a lottery ticket where for $4, you get a chance to "win" hundreds.